← SynDRA
DAPAGLIFLOZIN
SynDRA canonical compound SYN0009292 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | SLC5A1 | SLC5A2 |
|---|
| Mechanism of action | sodium/glucose cotransporter inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- SLC5A2
- SLC5A1
- SLC5A11
- SLC5A4
- Slc5a2
Mechanisms of action (all sources)
- SLC5A2 INHIBITOR
- Sodium/glucose cotransporter 2 inhibitor
- sodium/glucose cotransporter inhibitor
- SLC5A2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRA2A
- ABL1
- HTR3A
- MLNR
- MC4R
- MC3R
- MAPK1
- MAOA
- KDR
- KCNH2
- HTR2C
- NR3C1
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- NPY1R
- OPRD1
- GSK3B
- SLC29A1
- TBXA2R
- SLC6A4
- SLC6A3
- SLC6A2
- SLC2A4
- SLC2A1
- PTGS2
- OPRK1
- PTGS1
- PGR
- PDE4D
- PDE4A
- PDE3A
- OPRM1
- HDAC6
- GHSR
- ACHE
- ADRB2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
- Sodium-Glucose Cotransporter 2 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
- DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE
- FARXIGA
- Farxiga
- QTERN
- QTERNMET XR
- XIGDUO XR
- dapagliflozin propanediol monohydrate
- dapagliflozin propanediol
- BMS 512148
- forxiga
- dapaglifozin
- farxiga
- dapagliflozin propylene glycolate hydrate
- Dapagliflozine
- Dapagliflozina
- BMS-512148
- LYN-045
- Dapagliflozin component of br1019
- Dapagliflozin component of qtern
- Dapagliflozin component of qternmet
- Dapagliflozin component of qternmet dapaglifozin
- Dapagliflozin component of qternmet xr
- Dapagliflozin viatris
- BMS-512148, Dapagliflozin
- Dapagliflozin (INN/USAN)
- BR1019 component Dapagliflozin
- QTERNMET COMPONENT DAPAGLIFOZIN
- 1ULL0QJ8UC
- QTERNMET XR COMPONENT DAPAGLIFLOZIN
- DAPAGLIFLOZIN COMPONENT QTERNMET
- dapagliflozine
- CHEBI:85078
- BMS512148
- dapagliflozinum
- RefChem:54930
- A10BK01
Reported adverse events
- Rash
- Urinary tract infection
- Escherichia urinary tract infection
- Constipation
- Back pain
- Infection
- Hypersensitivity
- Ketoacidosis
- Pyelonephritis
- Urosepsis
- Influenza
- Nasopharyngitis
Look up DAPAGLIFLOZIN in the interactive SynDRA portal →